Britain's largest drugmaker intends to spend $2billion upfront for the Canadian firm, equivalent to $21 per share, followed by up to $400million in potential contingent payments.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.